Share capital and share prices change especially in a very small relatively illiquid market like Australia’s.
if AHF gets FDA approval and with the institutional placements going on, AHF’s takeover of A2M or merger, is plausible if IMHO not immediately likely.
The AHF bid for A2M or merger, or reverse TO, appears to be the only TO Bid for A2M plausible at this stage.
Yili and Mengniu are IMHO more likely to go after AHF than A2M if allowed given the Beijing coup and end of Xi Jinping rule would probably have to happen first?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)